Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP-751,871 plus docetaxel vs docetaxel alone in first-line treatment of advanced breast cancer
2008-001298-13Phase 2Terminated
- Sponsor
- Pfizer
- Start
- May 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of figitumumab in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Progression Free Survival. Started May 2008; status: terminated.
02
Drugs
figitumumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-001298-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001298-13.